Pembrolizumab Now Second Immunotherapy Approved to Treat Merkel Cell Carcinoma

FDA has approved pembrolizumab (Keytruda) to treat people with Merkel cell carcinoma, a rare and deadly form of skin cancer. The approval covers use of the drug to treat locally advanced or metastatic forms of the disease.



from Cancer Currents: An NCI Cancer Research Blog http://bit.ly/2Gn5nWO
Post a Comment (0)
Previous Post Next Post